Advertisement

Toxic Shock Syndrome

Fever, Erythroderma, Conjunctivitis, Shock
  • Tsoline Kojaoghlanian
Chapter

Abstract

Dr. James Todd first described toxic shock syndrome (TSS) in 1978. His case series report included seven children and adolescents who presented with a high fever, headache, confusion, conjunctival hyperemia, a scarlatiniform rash, subcutaneous edema, vomiting, watery diarrhea, and oliguria leading to severe, prolonged shock. Consistent laboratory findings included evidence of acute renal failure, liver injury, and dysfunction and disseminated intravascular coagulation. One patient died, one developed gangrene of the toes, and all six survivors developed desquamation of the skin on their hands and feet during convalescence. Staphylococcus aureus (S. aureus) was isolated from mucosal (nasopharyngeal, vaginal, tracheal), or sequestered (empyema, abscess) sites, but not from blood. These isolates produced an exotoxin, which caused a positive Nikolsky sign when inoculated into a newborn mouse. In the years that followed, the reported association of TSS with high absorbency tampon use garnered substantial media attention and delivered an important public health message albeit with more hyperbole than necessary. During that era, statements from Dr. Todd about “the myths, partial truths, and gross misconceptions promulgated in the media” sought to bring better education and additional perspective to the problem. Years later, the term “superantigen” was coined to describe a stimulus that causes a substantial expansion and proliferation of T lymphocytes leading to massive production and release of pro-inflammatory cytokines including tumor necrosis factor (TNF)-α and interleukin (IL)-1, IL-2, and IL-6. The inflammatory response is responsible for the clinical signs and symptoms seen in the patient with TSS. The end result of this intense cascade of events is life-threatening cardiovascular collapse. TSS is thus mediated by a complex interaction of superantigens with the host that results in extensive immune dysregulation and multi-organ dysfunction. Infections caused by Gram-positive organisms that produce superantigens, such as toxic shock syndrome toxin-1 (TSST-1) and enterotoxins SEB and SEC, produced by some strains of S. aureus, and streptococcal pyrogenic exotoxin A (SPE-A), produced by some strains of Streptococcus pyogenes, can lead to TSS. Clinically, TSS is an acute systemic illness, characterized by fever, hypotension, and involvement of at least two or more organ systems. Established case definitions exist for TSS caused by strains of S. aureus and S. pyogenes with some important differences between the two.

Keywords

Toxic shock syndrome Staphylococcus aureus Streptococcus pyogenes superantigens 

References

  1. 1.
    Todd J, et al. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;2(8100):1116–8.CrossRefGoogle Scholar
  2. 2.
    Schlievert PM, et al. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J. Infect. Dis. 1981;143(4):509–16.CrossRefGoogle Scholar
  3. 3.
    Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990;248(4956):705–11.CrossRefGoogle Scholar
  4. 4.
    Quan L, et al. Toxic shock syndrome toxin-1 (TSST-1) antibody levels in Japanese children. Burns. 2010;36(5):716–21.CrossRefGoogle Scholar
  5. 5.
    Kimber I, et al. Toxic shock syndrome: characterization of human immune responses to TSST-1 and evidence for sensitivity thresholds. Toxicol. Sci. 2013;134(1):49–63.CrossRefGoogle Scholar
  6. 6.
    Herwald H, Cramer H, Morgelin M, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell. 2004;116:367–79.CrossRefGoogle Scholar
  7. 7.
    Brown E. The molecular basis of streptococcal toxic shock syndrome. NEJM. 2004;350(20):2093.CrossRefGoogle Scholar
  8. 8.
    Lesko SM, et al. Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella. Pediatrics. 2001;107(5):1108–15.CrossRefGoogle Scholar
  9. 9.
    Chan KH, et al. Toxic shock syndrome and rhinosinusitis in children. Arch. Otolaryngol. Head Neck Surg. 2009;135(6):538–42.CrossRefGoogle Scholar
  10. 10.
    Laupland KB, et al. Invasive group A streptococcal disease in children and association with varicella-zoster virus infection. Pediatrics. 2000;105(5):E60.CrossRefGoogle Scholar
  11. 11.
    Imohl M, et al. Invasive group A streptococcal disease and association with varicella in Germany, 1996–2009. FEMS Immunol. Med. Microbiol. 2011;62:101–9.CrossRefGoogle Scholar
  12. 12.
    Patel RA, et al. Reduction in pediatric hospitalizations for varicella-related invasive group A streptococcal infections in the varicella vaccine era. J. Pediatr. 2004;144(1):68–74.CrossRefGoogle Scholar
  13. 13.
    Chiang, et al. Streptococcal toxic shock syndrome in children without skin and soft tissue infection: report of four cases. Acta Paediatr. 2005;94(6):763–5.CrossRefGoogle Scholar
  14. 14.
    Chen KYH, et al. Toxic shock syndrome in Australian children. Arch. Dis. Child. 2016;101:736–40.CrossRefGoogle Scholar
  15. 15.
    Davies HD, et al. Apparent lower rates of streptococcal toxic shock syndrome and lower mortality in children with invasive group A streptococcal infections compared with adults. Pediatr Infect Dis J. 1994;13(1):49–5.CrossRefGoogle Scholar
  16. 16.
    O’Loughlin RE, et al. The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin. Infect. Dis. 2007;45(7):853–62.CrossRefGoogle Scholar
  17. 17.
    Adalat S, et al. Toxic shock syndrome surveillance in UK children. Arch. Dis. Child. 2014;99(12):1078–82.CrossRefGoogle Scholar
  18. 18.
    Nigel C. Toxic shock syndrome: under-recognised and under-treated? Arch Dis Child December. 2014;99(12):1062–4.Google Scholar
  19. 19.
    Burnett AM, Domachowske JB. Therapeutic considerations for children with invasive group A streptococcal infections: a case series report and review of the literature. Clin Pediatr (Phila). 2007;46:550–5.CrossRefGoogle Scholar
  20. 20.
    Darenberg J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European. Clin. Infect. Dis. 2003;37:333–40.CrossRefGoogle Scholar
  21. 21.
    Carapetis J, et al. Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group A streptococcal infections. Clin. Infect. Dis. 2014;59:358–65.CrossRefGoogle Scholar
  22. 22.
    Shah S, et al. Intravenous immunoglobulin in children with streptococcal toxic shock syndrome. Clin. Infect. Dis. 2009;49:1369–76.CrossRefGoogle Scholar
  23. 23.
    Valiquette L, et al. Assessing the impact of intravenous immunoglobulin in the Management of Streptococcal Toxic Shock Syndrome: a Noble but difficult quest. Clin. Infect. Dis. 2009;49:1377.CrossRefGoogle Scholar
  24. 24.
    Red Book. Report of the committee on infectious diseases. American Academy of Pediatrics. 2015.Google Scholar
  25. 25.
    Allen U, Moore D. Invasive group A streptococcal disease: management and chemoprophylaxis. Paediatr. Child Health. 2010;15:295–302.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Tsoline Kojaoghlanian
    • 1
  1. 1.Department of PediatricsSBH Health System, Albert Einstein College of MedicineBronxUSA

Personalised recommendations